OBIO

In the past six months, Orchestra BioMed Holdings, Inc. experienced several stock-impacting events. On October 1, 2026, the company exceeded its full enrollment target in the BACKBEAT Global Pivotal Trial of AVIM Therapy, randomizing 330 patients. On September 16, 2026, AVIM Therapy was featured in two sessions at HRX Live 2026, highlighting its collaboration with Medtronic. The company received a $6.1 million milestone payment on September 15, 2026, from the acquisition of Vivasure by Haemonetics, bringing total cash proceeds to approximately $11 million. On September 2, 2026, Orchestra BioMed announced inducement grants under Nasdaq Listing Rule 5635(c)(4). The company also participated in the H.C. Wainwright 28th Annual Global Investment Conference on September 16, 2026, and the Wells Fargo 21st Annual Healthcare Conference on September 10, 2026. As of September 25, 2026, the stock price was $5.96 per share, marking a 145.47% increase from $2.43 per share on September 25, 2025. The stock was up 13.12% over the past 30 days and up 144.86% for the past 12 months as of September 28, 2026, with its 52-week range between $2.78 and $6.50.